Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NeuroOne Medical Technologies ( (NMTC) ) has provided an announcement.
On December 18, 2025, NeuroOne’s board expanded from four to five members and appointed Jason R. Mills as a Class I director, with his committee roles on the Compensation and Nominating & Corporate Governance Committees effective January 1, 2025, a move publicly announced on December 22, 2025. Mills, currently Executive Vice President of Strategy at Penumbra and a former award-winning med-tech equity research analyst, brings deep industry, strategic and capital markets experience that NeuroOne’s leadership believes will support its clinical and corporate objectives and help broaden its reach as it seeks to advance and commercialize its neurological disorder treatment technologies; on the same day, the company also posted an updated corporate presentation to its investor website to support ongoing communications with the market.
The most recent analyst rating on (NMTC) stock is a Hold with a $0.68 price target. To see the full list of analyst forecasts on NeuroOne Medical Technologies stock, see the NMTC Stock Forecast page.
Spark’s Take on NMTC Stock
According to Spark, TipRanks’ AI Analyst, NMTC is a Neutral.
NeuroOne Medical Technologies shows strong revenue growth and strategic market expansions, which are significant positives. However, ongoing profitability and cash flow challenges, along with a bearish technical outlook and negative valuation metrics, weigh heavily on the overall score.
To see Spark’s full report on NMTC stock, click here.
More about NeuroOne Medical Technologies
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is a medical technology company focused on developing and commercializing minimally invasive, high-definition solutions for EEG recording, monitoring, ablation, drug delivery and stimulation aimed at improving the surgical diagnosis and treatment of neurological disorders, including epilepsy, Parkinson’s disease, dystonia, essential tremors and chronic pain from failed back surgeries, with potential applications in areas such as depression, mood disorders, pain, incontinence, high blood pressure and artificial intelligence.
Average Trading Volume: 326,254
Technical Sentiment Signal: Strong Sell
Current Market Cap: $37.01M
For detailed information about NMTC stock, go to TipRanks’ Stock Analysis page.